FEBS letters · 2022
Combinatorial pathway disruption is a powerful approach to delineate metabolic impacts of endocrine disruptors.
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bernal Kévin, Touma Charbel, Erradhouani Chedi, Boronat-Belda Talía, Gaillard Lucas, Al Kassir Sara, Le Mentec Hélène, Martin-Chouly Corinne, Podechard Normand, Lagadic-Gossmann Dominique, Langouet Sophie, Brion François, Knoll-Gellida Anja, Babin Patrick J, Sovadinova Iva, Babica Pavel, Andreau Karine, Barouki Robert, Vondracek Jan, Alonso-Magdalena Paloma, Blanc Etienne, Kim Min Ji, Coumoul Xavier
Аннотация
The prevalence of metabolic diseases, such as obesity, diabetes, metabolic syndrome and chronic liver diseases among others, has been rising for several years. Epidemiology and mechanistic (in vivo, in vitro and in silico) toxicology have recently provided compelling evidence implicating the chemical environment in the pathogenesis of these diseases. In this review, we will describe the biological processes that contribute to the development of metabolic diseases targeted by metabolic disruptors, and will propose an integrated pathophysiological vision of their effects on several organs. With regard to these pathomechanisms, we will discuss the needs, and the stakes of evolving the testing and assessment of endocrine disruptors to improve the prevention and management of metabolic diseases that have become a global epidemic since the end of last century.